Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + pirarubicin
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Capecitabine + pirarubicin (AX regimen) is a combination chemotherapy used primarily as adjuvant treatment for breast cancer. Capecitabine is an oral fluoropyrimidine prodrug that is converted to 5-fluorouracil (5-FU) by enzymes expressed in higher concentrations in tumor tissues. Pirarubicin is an anthracycline that interferes with DNA synthesis. This combination has shown efficacy comparable to the AC regimen (pirarubicin and cyclophosphamide) in node-negative breast cancer patients, with fewer severe toxicities and better quality of life outcomes.
- Other names
- AX regimen
02
Targets
TOP2A (DNA topoisomerase II)TYMP (Thymidine phosphorylase)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on capecitabine + pirarubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + pirarubicin.